Conference/Events
|
Biopharma/Biotech… Biopharma/Biotech Analysts Chen & Kim and Biotech Analyst Kluska, along with KOL speakers Dr. Dahiya, Asssoc Prof at University of Maryland and Dr. Ruella, Asst Prof at University of Pennsylvania discuss how next-generation CAR-T therapies could expand the market opportunity for these companies' treatments, including NVS, GILD, BMY, JNJ, GRCL, PSTX, PGEN, MBIO, ACLX, ALLO, FATE and HARP on an Analyst/Industry conference call to be held on December 14 at 1 pm. Webcast Link ShowHide Related Items >><< PSTX Poseida Therapeutics - 12/11/22
- Poseida presents preclinical data from P-FVIII-101 gene therapy for hemophilia A
- 10/05/22
- Poseida Therapeutics to present trial in progress poster for Phase 1 study
- 08/11/22
- Poseida Therapeutics expects cash to fund operations into at least mid-2024
- 06/29/22
- Poseida Therapeutics' Gene Editing System shows efficacy in published study
- 12/12/22
- Precigen announces 'positive' Phase 1 dose escalation data from PRGN-3006 study
- 09/21/22
- Precigen names names Rutul Shah COO
- 08/08/22
- Precigen expectsTrans Ova Genetics sale to close in Q3
- 07/05/22
- Precigen enters agreement to divest non-healthcare subsidiary Trans Ova to URUS
- 12/14/22
- Harrow Health signs binding agreement to acquire rights to ophthalmic products
- 12/13/22
- Novartis reports Phase 3 APPLY-PNH trial met both primary endpoints
- 12/12/22
- Clovis files for Chapter 11 protection, enters agreement to sell FAP-228
- 12/09/22
- Erasca, Novartis enter worldwide license agreement for naporafenib
- 10/27/22
- Mustang Bio announces Phase 1/2 trial data of MB-106
- 10/06/22
- Mustang Bio treats first patient in Phase 1/2 trial of MB-106
- 07/27/22
- Mustang Bio announces first patient treated by ex vivo lentiviral gene therapy
- 06/22/22
- Mustang Bio announces FDA granted ODD to MB-106
- 12/14/22
- J&J announces extension of Abiomed tender offer to December 21
- 12/12/22
- Janssen announces new analyses from Phase 3 MAIA study of Darzalex
- 12/09/22
- Janssen submits BLA for talquetamab for RRMM to FDA
- 12/05/22
- J&J says 'it does not intent to make offer' for Horizon Therapeutics
HARP Harpoon Therapeutics - 12/11/22
- Harpoon presents interim results from Phase 1 evaluating single-agent HPN217
- 10/04/22
- Harpoon Therapeutics appoints Luke Walker as Chief Medical Officer
- 08/10/22
- Harpoon Therapeutics announces CFO Georgia Erbez to depart
- 07/06/22
- Harpoon Therapeutics appoints Wendy Chang as SVP, human resources
- 10/17/22
- Gracell doses first patients in Phase 2 trial of leukemia candidate GC007g
- 08/15/22
- Gracell sees cash runway into 2024
- 08/01/22
- Gracell names Dr. Wendy Li as Chief Medical Officer
- 07/19/22
- Gracell names Dr. Samuel Zhang as Chief Business Officer
- 12/12/22
- Kite announces three-year follow-up data from Yescarta therapy
- 12/12/22
- Kite announces findings from followup of ZUMA-2, ZUMA-3 studies
- 12/11/22
- Kite announces findings from two new analyses of ZUMA-7 trial of Yescarta
- 12/09/22
- Gilead subsidiary enters CART-ddBCMA commercialization agreement, sees dilution
- 12/13/22
- Fate Therapeutics announces data on approaches to cancer immunotherapies
- 12/12/22
- GT Biopharma, Fate present preclinical data on dual antigen targeting approach
- 12/11/22
- Fate presents interim data from dose-escalation stage of Phase 1 study of FT819
- 12/11/22
- Fate presents interim clinical data from ongoing Phase 1 stuty of FT576
- 12/12/22
- Bristol-Myers announces first disclosures, new data at ASH 2022
- 12/08/22
- Bristol-Myers raises quarterly dividend 5.6% to 54c per share
- 11/29/22
- Bristol-Myers, Envisagenics announce research collaboration
- 11/07/22
- Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports
ALLO Allogene Therapeutics - 11/29/22
- Allogene unveils Dagger technology during R&D showcase
- 11/10/22
- Allogene Therapeutics presents pre-clinical data on immune 'cloaking'
- 10/31/22
- Allogene Overland Biopharm completes buildout of cGMP manufacturing facility
- 10/11/22
- Allogene Therapeutics launches CART T Together
- 12/09/22
- Arcellx trading resumes
- 12/09/22
- Arcellx reports results from CART-ddBCMA Phase 1 expansion trial
- 12/09/22
- Arcellx, Kite collaborate to develop CART-ddBCMA
- 12/09/22
- Arcellx trading halted, news pending
- 12/05/22 Stifel
- Novartis upgraded to Buy from Hold at Stifel
- 10/26/22 JPMorgan
- Novartis price target lowered to CHF 78 from CHF 81 at JPMorgan
- 10/14/22 Barclays
- Novartis price target lowered to CHF 75 from CHF 85 at Barclays
- 10/07/22 Deutsche Bank
- Novartis price target lowered to CHF 70 from CHF 75 at Deutsche Bank
- 12/13/22 BofA
- Gilead resumed with a Neutral at BofA
- 12/12/22 Needham
- Arcellx price target raised to $35 from $31 at Needham
- 12/09/22 Piper Sandler
- Gilead price target raised to $104 from $96 at Piper Sandler
- 12/09/22 DZ Bank
- Gilead downgraded to Hold from Buy at DZ Bank
- 11/17/22 Credit Suisse
- Bristol-Myers initiated with a Neutral at Credit Suisse
- 11/17/22 Morgan Stanley
- Ventyx Biosciences initiated with an Overweight at Morgan Stanley
- 11/14/22 BMO Capital
- CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- 11/02/22 Evercore ISI
- Evercore starts Legend Biotech with an Outperform on Carvykti potential
- 12/12/22 Citi
- Johnson & Johnson price target raised to $205 from $198 at Citi
- 12/07/22 Piper Sandler
- Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler
- 12/01/22 Jefferies
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- 12/01/22 Morgan Stanley
- Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
- 12/08/22 H.C. Wainwright
- Gracell initiated with a Buy at H.C. Wainwright
- 09/22/22 Citi
- Gracell initiated with a Buy at Citi
- 08/18/22 Wells Fargo
- Gracell assumed with an Overweight at Wells Fargo
- 06/01/22 Cantor Fitzgerald
- Gracell initiated with an Overweight at Cantor Fitzgerald
PSTX Poseida Therapeutics - 11/11/22 BTIG
- Poseida Therapeutics price target lowered to $14 from $20 at BTIG
- 08/09/22 Piper Sandler
- Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
- 05/13/22 BTIG
- Poseida Therapeutics price target lowered to $20 from $40 at BTIG
- 05/13/22 Piper Sandler
- Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
- 11/18/22 Cantor Fitzgerald
- Precigen initiated with an Overweight at Cantor Fitzgerald
- 11/18/22 Cantor Fitzgerald
- Precigen initiated with an Overweight at Cantor Fitzgerald
- 08/09/22 H.C. Wainwright
- Precigen price target lowered to $6 from $10 at H.C. Wainwright
- 07/05/22 Stifel
- Precigen subsidiary sale relieves convertible debt overhang, says Stifel
- 11/16/22 BTIG
- Mustang Bio price target lowered to $4 from $8 at BTIG
- 08/17/22 BTIG
- Bluebird's approval has positive read for Mustang Bio, says BTIG
- 07/14/22 B. Riley
- Mustang Bio price target lowered to $4 from $5 at B. Riley
- 05/23/22 B. Riley
- Mustang Bio price target lowered to $5 from $6 at B. Riley
- 12/13/22 BofA
- Arcellx resumed with a Buy at BofA
- 12/12/22 Canaccord
- Arcellx price target raised to $34 from $32 at Canaccord
- 12/12/22 Barclays
- Arcellx price target raised to $38 from $25 at Barclays
ALLO Allogene Therapeutics - 12/12/22 BofA
- Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
- 12/12/22 BofA
- Allogene Therapeutics downgraded to Underperform from Buy at BofA
- 11/21/22 H.C. Wainwright
- Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
- 09/22/22 B. Riley
- Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
- 12/13/22 Truist
- Fate Therapeutics price target lowered to $46 from $51 at Truist
- 12/12/22 Oppenheimer
- Fate Therapeutics price target lowered to $65 from $90 at Oppenheimer
- 11/16/22 Citi
- Fate Therapeutics price target lowered to $80 from $87 at Citi
- 11/04/22 Cantor Fitzgerald
- Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
HARP Harpoon Therapeutics - 12/14/22 Truist
- Harpoon Therapeutics downgraded to Hold from Buy at Truist
- 11/15/22 Baird
- Harpoon Therapeutics downgraded to Neutral from Outperform at Baird
- 08/29/22 Citi
- Harpoon Therapeutics price target lowered to $6 from $7 at Citi
- 08/23/22 Truist
- Harpoon Therapeutics price target lowered to $7 from $12 at Truist
PSTX Poseida Therapeutics - 11/10/22
- Poseida Therapeutics reports Q3 EPS 92c, consensus (65c)
- 08/11/22
- Poseida Therapeutics reports Q2 EPS (69c) vs (74c) last year
- 11/09/22
- Precigen reports Q3 EPS (4c), consensus 2c
- 08/08/22
- Precigen reports Q2 EPS (13c), consensus (16c)
- 10/25/22
- Novartis confirms mid single digit sales, core operating income guidance
- 10/25/22
- Novartis reports Q3 core EPS $1.58 vs. $1.71 last year
- 09/22/22
- Novartis sees 4% sales CAGR through 2027
- 07/19/22
- Novartis reports Q2 core EPS $1.56 vs. $1.66 a year ago
- 11/14/22
- Mustang Bio reports Q3 EPS (18c), consensus (20c)
- 10/18/22
- Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07
- 10/18/22
- Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48
HARP Harpoon Therapeutics - 11/14/22
- Harpoon Therapeutics reports Q3 EPS (35c), consensus (56c)
- 08/10/22
- Harpoon Therapeutics reports Q2 EPS (53c), consensus (56c)
- 11/14/22
- Gracell reports Q3 EPS (7c), consensus (13c)
- 08/15/22
- Gracell reports Q2 EPS (6c), consensus (7c)
- 10/27/22
- Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75
- 10/27/22
- Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43
- 10/27/22
- Notable companies reporting after market close
- 08/02/22
- Gilead raises FY22 adjusted EPS view $6.35-$6.75 from $6.20-$6.70
- 11/03/22
- Fate Therapeutics reports Q3 EPS (86c), consensus (89c)
- 08/03/22
- Fate Therapeutics reports Q2 EPS (79c), consensus (83c)
- 10/25/22
- Notable companies reporting before tomorrow's open
- 10/25/22
- Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51
- 10/25/22
- Bristol-Myers reports Q3 EPS $1.99, consensus $1.83
ALLO Allogene Therapeutics - 08/09/22
- Allogene Therapeutics reports Q2 EPS (52c), consensus (61c)
- 11/14/22
- Arcellx reports Q3 EPS ($2.12), consensus (89c)
- 08/15/22
- Arcellx reports Q2 EPS (88c), consensus ($1.07)
|
Conference/Events
|
Biopharma/Biotech… Biopharma/Biotech Analysts Chen & Kim and Biotech Analyst Kluska, along with KOL speakers Dr. Dahiya, Asssoc Prof at University of Maryland and Dr. Ruella, Asst Prof at University of Pennsylvania discuss how next-generation CAR-T therapies could expand the market opportunity for these companies' treatments, including NVS, GILD, BMY, JNJ, GRCL, PSTX, PGEN, MBIO, ACLX, ALLO, FATE and HARP on an Analyst/Industry conference call to be held on December 14 at 1 pm. Webcast Link ShowHide Related Items >><< PSTX Poseida Therapeutics - 12/11/22
- Poseida presents preclinical data from P-FVIII-101 gene therapy for hemophilia A
- 10/05/22
- Poseida Therapeutics to present trial in progress poster for Phase 1 study
- 08/11/22
- Poseida Therapeutics expects cash to fund operations into at least mid-2024
- 06/29/22
- Poseida Therapeutics' Gene Editing System shows efficacy in published study
- 12/12/22
- Precigen announces 'positive' Phase 1 dose escalation data from PRGN-3006 study
- 09/21/22
- Precigen names names Rutul Shah COO
- 08/08/22
- Precigen expectsTrans Ova Genetics sale to close in Q3
- 07/05/22
- Precigen enters agreement to divest non-healthcare subsidiary Trans Ova to URUS
- 12/13/22
- Novartis reports Phase 3 APPLY-PNH trial met both primary endpoints
- 12/12/22
- Clovis files for Chapter 11 protection, enters agreement to sell FAP-228
- 12/09/22
- Erasca, Novartis enter worldwide license agreement for naporafenib
- 12/08/22
- Novartis reports Phase 3 APPOINT-PNH study met primary endpoint
- 10/27/22
- Mustang Bio announces Phase 1/2 trial data of MB-106
- 10/06/22
- Mustang Bio treats first patient in Phase 1/2 trial of MB-106
- 07/27/22
- Mustang Bio announces first patient treated by ex vivo lentiviral gene therapy
- 06/22/22
- Mustang Bio announces FDA granted ODD to MB-106
- 12/12/22
- Janssen announces new analyses from Phase 3 MAIA study of Darzalex
- 12/09/22
- Janssen submits BLA for talquetamab for RRMM to FDA
- 12/05/22
- J&J says 'it does not intent to make offer' for Horizon Therapeutics
- 12/05/22
- Yumanity declares special dividend related to asset sale, merger with Kineta
HARP Harpoon Therapeutics - 12/11/22
- Harpoon presents interim results from Phase 1 evaluating single-agent HPN217
- 10/04/22
- Harpoon Therapeutics appoints Luke Walker as Chief Medical Officer
- 08/10/22
- Harpoon Therapeutics announces CFO Georgia Erbez to depart
- 07/06/22
- Harpoon Therapeutics appoints Wendy Chang as SVP, human resources
- 10/17/22
- Gracell doses first patients in Phase 2 trial of leukemia candidate GC007g
- 08/15/22
- Gracell sees cash runway into 2024
- 08/01/22
- Gracell names Dr. Wendy Li as Chief Medical Officer
- 07/19/22
- Gracell names Dr. Samuel Zhang as Chief Business Officer
- 12/12/22
- Kite announces three-year follow-up data from Yescarta therapy
- 12/12/22
- Kite announces findings from followup of ZUMA-2, ZUMA-3 studies
- 12/11/22
- Kite announces findings from two new analyses of ZUMA-7 trial of Yescarta
- 12/09/22
- Gilead subsidiary enters CART-ddBCMA commercialization agreement, sees dilution
- 12/13/22
- Fate Therapeutics announces data on approaches to cancer immunotherapies
- 12/12/22
- GT Biopharma, Fate present preclinical data on dual antigen targeting approach
- 12/11/22
- Fate presents interim data from dose-escalation stage of Phase 1 study of FT819
- 12/11/22
- Fate presents interim clinical data from ongoing Phase 1 stuty of FT576
- 12/12/22
- Bristol-Myers announces first disclosures, new data at ASH 2022
- 12/08/22
- Bristol-Myers raises quarterly dividend 5.6% to 54c per share
- 11/29/22
- Bristol-Myers, Envisagenics announce research collaboration
- 11/07/22
- Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports
ALLO Allogene Therapeutics - 11/29/22
- Allogene unveils Dagger technology during R&D showcase
- 11/10/22
- Allogene Therapeutics presents pre-clinical data on immune 'cloaking'
- 10/31/22
- Allogene Overland Biopharm completes buildout of cGMP manufacturing facility
- 10/11/22
- Allogene Therapeutics launches CART T Together
- 12/09/22
- Arcellx trading resumes
- 12/09/22
- Arcellx reports results from CART-ddBCMA Phase 1 expansion trial
- 12/09/22
- Arcellx, Kite collaborate to develop CART-ddBCMA
- 12/09/22
- Arcellx trading halted, news pending
- 12/05/22 Stifel
- Novartis upgraded to Buy from Hold at Stifel
- 10/26/22 JPMorgan
- Novartis price target lowered to CHF 78 from CHF 81 at JPMorgan
- 10/14/22 Barclays
- Novartis price target lowered to CHF 75 from CHF 85 at Barclays
- 10/07/22 Deutsche Bank
- Novartis price target lowered to CHF 70 from CHF 75 at Deutsche Bank
- 12/13/22 BofA
- Gilead resumed with a Neutral at BofA
- 12/12/22 Needham
- Arcellx price target raised to $35 from $31 at Needham
- 12/09/22 Piper Sandler
- Gilead price target raised to $104 from $96 at Piper Sandler
- 12/09/22 DZ Bank
- Gilead downgraded to Hold from Buy at DZ Bank
- 11/17/22 Credit Suisse
- Bristol-Myers initiated with a Neutral at Credit Suisse
- 11/17/22 Morgan Stanley
- Ventyx Biosciences initiated with an Overweight at Morgan Stanley
- 11/14/22 BMO Capital
- CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- 11/02/22 Evercore ISI
- Evercore starts Legend Biotech with an Outperform on Carvykti potential
- 12/12/22 Citi
- Johnson & Johnson price target raised to $205 from $198 at Citi
- 12/07/22 Piper Sandler
- Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler
- 12/01/22 Jefferies
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- 12/01/22 Morgan Stanley
- Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
- 12/08/22 H.C. Wainwright
- Gracell initiated with a Buy at H.C. Wainwright
- 09/22/22 Citi
- Gracell initiated with a Buy at Citi
- 08/18/22 Wells Fargo
- Gracell assumed with an Overweight at Wells Fargo
- 06/01/22 Cantor Fitzgerald
- Gracell initiated with an Overweight at Cantor Fitzgerald
PSTX Poseida Therapeutics - 11/11/22 BTIG
- Poseida Therapeutics price target lowered to $14 from $20 at BTIG
- 08/09/22 Piper Sandler
- Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
- 05/13/22 BTIG
- Poseida Therapeutics price target lowered to $20 from $40 at BTIG
- 05/13/22 Piper Sandler
- Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
- 11/18/22 Cantor Fitzgerald
- Precigen initiated with an Overweight at Cantor Fitzgerald
- 11/18/22 Cantor Fitzgerald
- Precigen initiated with an Overweight at Cantor Fitzgerald
- 08/09/22 H.C. Wainwright
- Precigen price target lowered to $6 from $10 at H.C. Wainwright
- 07/05/22 Stifel
- Precigen subsidiary sale relieves convertible debt overhang, says Stifel
- 11/16/22 BTIG
- Mustang Bio price target lowered to $4 from $8 at BTIG
- 08/17/22 BTIG
- Bluebird's approval has positive read for Mustang Bio, says BTIG
- 07/14/22 B. Riley
- Mustang Bio price target lowered to $4 from $5 at B. Riley
- 05/23/22 B. Riley
- Mustang Bio price target lowered to $5 from $6 at B. Riley
- 12/13/22 BofA
- Arcellx resumed with a Buy at BofA
- 12/12/22 Canaccord
- Arcellx price target raised to $34 from $32 at Canaccord
- 12/12/22 Barclays
- Arcellx price target raised to $38 from $25 at Barclays
ALLO Allogene Therapeutics - 12/12/22 BofA
- Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
- 12/12/22 BofA
- Allogene Therapeutics downgraded to Underperform from Buy at BofA
- 11/21/22 H.C. Wainwright
- Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
- 09/22/22 B. Riley
- Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
- 12/13/22 Truist
- Fate Therapeutics price target lowered to $46 from $51 at Truist
- 12/12/22 Oppenheimer
- Fate Therapeutics price target lowered to $65 from $90 at Oppenheimer
- 11/16/22 Citi
- Fate Therapeutics price target lowered to $80 from $87 at Citi
- 11/04/22 Cantor Fitzgerald
- Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
HARP Harpoon Therapeutics - 11/15/22 Baird
- Harpoon Therapeutics downgraded to Neutral from Outperform at Baird
- 08/29/22 Citi
- Harpoon Therapeutics price target lowered to $6 from $7 at Citi
- 08/23/22 Truist
- Harpoon Therapeutics price target lowered to $7 from $12 at Truist
- 08/15/22 H.C. Wainwright
- Harpoon Therapeutics price target lowered to $7 from $18 at H.C. Wainwright
PSTX Poseida Therapeutics - 11/10/22
- Poseida Therapeutics reports Q3 EPS 92c, consensus (65c)
- 08/11/22
- Poseida Therapeutics reports Q2 EPS (69c) vs (74c) last year
- 11/09/22
- Precigen reports Q3 EPS (4c), consensus 2c
- 08/08/22
- Precigen reports Q2 EPS (13c), consensus (16c)
- 10/25/22
- Novartis confirms mid single digit sales, core operating income guidance
- 10/25/22
- Novartis reports Q3 core EPS $1.58 vs. $1.71 last year
- 09/22/22
- Novartis sees 4% sales CAGR through 2027
- 07/19/22
- Novartis reports Q2 core EPS $1.56 vs. $1.66 a year ago
- 11/14/22
- Mustang Bio reports Q3 EPS (18c), consensus (20c)
- 10/18/22
- Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07
- 10/18/22
- Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48
HARP Harpoon Therapeutics - 11/14/22
- Harpoon Therapeutics reports Q3 EPS (35c), consensus (56c)
- 08/10/22
- Harpoon Therapeutics reports Q2 EPS (53c), consensus (56c)
- 11/14/22
- Gracell reports Q3 EPS (7c), consensus (13c)
- 08/15/22
- Gracell reports Q2 EPS (6c), consensus (7c)
- 10/27/22
- Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75
- 10/27/22
- Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43
- 10/27/22
- Notable companies reporting after market close
- 08/02/22
- Gilead raises FY22 adjusted EPS view $6.35-$6.75 from $6.20-$6.70
- 11/03/22
- Fate Therapeutics reports Q3 EPS (86c), consensus (89c)
- 08/03/22
- Fate Therapeutics reports Q2 EPS (79c), consensus (83c)
- 10/25/22
- Notable companies reporting before tomorrow's open
- 10/25/22
- Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51
- 10/25/22
- Bristol-Myers reports Q3 EPS $1.99, consensus $1.83
ALLO Allogene Therapeutics - 08/09/22
- Allogene Therapeutics reports Q2 EPS (52c), consensus (61c)
- 11/14/22
- Arcellx reports Q3 EPS ($2.12), consensus (89c)
- 08/15/22
- Arcellx reports Q2 EPS (88c), consensus ($1.07)
|